source
- FDA rejects Capricor's Duchenne cell therapy again, citing major trial flawsCapricor Therapeutics' deramiocel cell therapy for Duchenne muscular dystrophy was denied by the FDA for a second time. The agency highlighted significant issues with the trial design and data, le…
- Biopharma newsletter released despite tech outages, highlights Washington political newsThe latest edition of a biopharma newsletter was published even though the week was marked by several technology outages. The issue notes that the most significant story came from Washington, wher…